Literature DB >> 30259184

A high number of IgG4-positive plasma cells rules out nodular lymphocyte predominant Hodgkin lymphoma.

Kati Kiil1, Julia Bein1, Bianca Schuhmacher1, Lorenz Thurner2, Markus Schneider1, Martin-Leo Hansmann1,3,4, Sylvia Hartmann5,6.   

Abstract

Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is a subtype of Hodgkin lymphoma that frequently shows a nodal growth pattern with abundant reactive B cells in the microenvironment. Early NLPHL cases can be particularly difficult to differentiate from progressively transformed germinal centers (PTGC). Since PTGC have been described to be IgG4 associated in a relatively high proportion of cases, the aim of the present study was to determine if IgG4 immunostaining can be helpful in the differential diagnosis between NLPHL and PTGC. We furthermore aimed to learn if LP cells can express IgG4. For this purpose, 58 cases of PTGC and 56 cases of NLPHL were assessed using IgG4 immunostaining. We could confirm that a significant number of PTGC cases showed high numbers of IgG4-positive plasma cells (22/58, 38%), whereas hot spot areas of IgG4-positive plasma cells were not found in any of the NLPHL cases. In lymph node areas with the differential diagnosis of NLPHL and PTGC, IgG4 immunostaining can therefore provide a helpful diagnostic tool to rule out NLPHL when a high number of IgG4-positive plasma cells are encountered. We also assessed 13 cases with a combination of NLPHL and PTGC in the same lymph node. Five of these cases presented hot spot areas of IgG4-positive plasma cells in the PTGC regions, while no significant numbers of IgG4-positive plasma cells were observed in the NLPHL part of the lymph node. LP cells were never IgG4 positive. Furthermore, immunoglobulin heavy chain rearrangements of single IgG4-positive plasma cells were analyzed, revealing a polyclonal plasma cell population. In summary, our data suggest that IgG4 immunostaining can provide additional information in the diagnostic workup of cases with the differential diagnosis of NLPHL and PTGC. IgG4's inefficiency in clearing antigens may explain why lymph nodes with PTGC are usually strongly enlarged and develop a high number of hyperplastic germinal centers. Polyclonal immunoglobulin heavy chain rearrangements in IgG4-positive plasma cells further support the hypothesis that PTGC represent a misled immune reaction.

Entities:  

Keywords:  IgG4-associated lymphadenopathy; IgG4-related disease; Nodular lymphocyte predominant Hodgkin lymphoma; Progressively transformed germinal centers

Mesh:

Substances:

Year:  2018        PMID: 30259184     DOI: 10.1007/s00428-018-2460-8

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  22 in total

1.  Immunoarchitectural patterns of progressive transformation of germinal centers with and without nodular lymphocyte-predominant Hodgkin lymphoma.

Authors:  Sylvia Hartmann; Ria Winkelmann; Ryan A Metcalf; Jitsupa Treetipsatit; Roger A Warnke; Yasodha Natkunam; Martin-Leo Hansmann
Journal:  Hum Pathol       Date:  2015-07-21       Impact factor: 3.466

2.  L and H cells of nodular lymphocyte predominant Hodgkin's disease show immunoglobulin light-chain restriction.

Authors:  C Schmid; C Sargent; P G Isaacson
Journal:  Am J Pathol       Date:  1991-12       Impact factor: 4.307

Review 3.  Consensus statement on the pathology of IgG4-related disease.

Authors:  Vikram Deshpande; Yoh Zen; John Kc Chan; Eunhee E Yi; Yasuharu Sato; Tadashi Yoshino; Günter Klöppel; J Godfrey Heathcote; Arezou Khosroshahi; Judith A Ferry; Rob C Aalberse; Donald B Bloch; William R Brugge; Adrian C Bateman; Mollie N Carruthers; Suresh T Chari; Wah Cheuk; Lynn D Cornell; Carlos Fernandez-Del Castillo; David G Forcione; Daniel L Hamilos; Terumi Kamisawa; Satomi Kasashima; Shigeyuki Kawa; Mitsuhiro Kawano; Gregory Y Lauwers; Yasufumi Masaki; Yasuni Nakanuma; Kenji Notohara; Kazuichi Okazaki; Ji Kon Ryu; Takako Saeki; Dushyant V Sahani; Thomas C Smyrk; James R Stone; Masayuki Takahira; George J Webster; Motohisa Yamamoto; Giuseppe Zamboni; Hisanori Umehara; John H Stone
Journal:  Mod Pathol       Date:  2012-05-18       Impact factor: 7.842

4.  IgG4 Expression in Primary Cutaneous Marginal Zone Lymphoma: A Multicenter Study.

Authors:  Aieska De Souza; Judith A Ferry; Daniel R Burghart; Marianne Tinguely; Amrita Goyal; Lyn M Duncan; Heinz Kutzner; Werner Kempf
Journal:  Appl Immunohistochem Mol Morphol       Date:  2018-08

5.  Laser-based microdissection of single cells from tissue sections and PCR analysis of rearranged immunoglobulin genes from isolated normal and malignant human B cells.

Authors:  Ralf Küppers; Markus Schneider; Martin-Leo Hansmann
Journal:  Methods Mol Biol       Date:  2013

Review 6.  IgG4 breaking the rules.

Authors:  Rob C Aalberse; Janine Schuurman
Journal:  Immunology       Date:  2002-01       Impact factor: 7.397

7.  Cytogenetic findings in nodular paragranuloma (Hodgkin's disease with lymphocytic predominance; nodular) and in progressively transformed germinal centers.

Authors:  M L Hansmann; E Gödde-Salz; P K Hui; H K Müller-Hermelink; K Lennert
Journal:  Cancer Genet Cytogenet       Date:  1986-04-15

8.  Progressive transformation of germinal centers with and without association to Hodgkin's disease.

Authors:  M L Hansmann; C Fellbaum; P K Hui; P Moubayed
Journal:  Am J Clin Pathol       Date:  1990-02       Impact factor: 2.493

9.  Association between IgG4-related disease and progressively transformed germinal centers of lymph nodes.

Authors:  Yasuharu Sato; Dai Inoue; Naoko Asano; Katsuyoshi Takata; Hideki Asaoku; Yoshinobu Maeda; Toshiaki Morito; Hirokazu Okumura; Shin Ishizawa; Shoko Matsui; Takayoshi Miyazono; Tamotsu Takeuchi; Naoto Kuroda; Yorihisa Orita; Kiyoshi Takagawa; Masaru Kojima; Tadashi Yoshino
Journal:  Mod Pathol       Date:  2012-04-06       Impact factor: 7.842

10.  Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q.

Authors:  C I Bindon; G Hale; M Brüggemann; H Waldmann
Journal:  J Exp Med       Date:  1988-07-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.